Last updated on August 2019

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.

Detailed Study Description

This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Clinical Study Identifier: NCT03403790

Find a site near you

Start Over

Site JP00007

Fukushima, Japan
  Connect »

Site JP00034

Hiroshima, Japan
  Connect »

Site JP00001

Hokkaido, Japan
  Connect »

Site JP00017

Ishikawa, Japan
  Connect »

Site JP00046

Kagoshima, Japan
  Connect »

Site JP00014

Kanagawa, Japan
  Connect »

Site JP00043

Kumamoto, Japan
  Connect »

Site JP00045

Miyazaki, Japan
  Connect »

Site JP00042

Nagasaki, Japan
  Connect »

Site JP00022

Shizuoka, Japan
  Connect »

Site JP00036

Tokushima, Japan
  Connect »

Site JP00030

Wakayama, Japan
  Connect »

Site JP00006

Yamagata, Japan
  Connect »

Site JP00035

Yamaguchi, Japan
  Connect »

Site JP00019

Yamanashi, Japan
  Connect »